Analyst Price Targets — ANAB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 21, 2026 12:28 pm | — | UBS | $60.00 | $54.23 | TheFly | AnaptysBio price target lowered to $60 from $90 at UBS |
| March 6, 2026 2:07 pm | John Lee | Truist Financial | $50.00 | $56.29 | StreetInsider | AnaptysBio (ANAB) PT Raised to $50 at Truist Securities on improved outlook for Jemperli |
| March 5, 2026 11:54 am | Alex Thompson | Stifel Nicolaus | $85.00 | $57.36 | StreetInsider | AnaptysBio (ANAB) PT Raised to $85 at Stifel After Q4 Update |
| March 4, 2026 11:41 am | Emily Bodnar | H.C. Wainwright | $66.00 | $58.04 | StreetInsider | AnaptysBio (ANAB) PT Raised to $66 at H.C. Wainwright |
| January 7, 2026 5:39 am | Michael Yee | UBS | $70.00 | $43.91 | StreetInsider | UBS Assumes AnaptysBio (ANAB) at Buy |
| December 18, 2025 1:24 pm | — | Guggenheim | $140.00 | $46.23 | TheFly | AnaptysBio price target raised to $140 from $100 at Guggenheim |
| December 17, 2025 10:54 am | Etzer Darout | Barclays | $55.00 | $45.03 | TheFly | AnaptysBio price target lowered to $55 from $70 at Barclays |
| December 11, 2025 12:13 pm | — | Stifel Nicolaus | $56.00 | $44.95 | TheFly | AnaptysBio price target lowered to $56 from $80 at Stifel |
| November 11, 2025 10:24 am | — | Barclays | $70.00 | $33.98 | TheFly | AnaptysBio price target lowered to $70 from $83 at Barclays |
| November 10, 2025 4:45 pm | David Nierengarten | Wedbush | $50.00 | $33.26 | TheFly | AnaptysBio price target lowered to $50 from $70 at Wedbush |
Latest News for ANAB
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business.
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) Director John Schmid sold 20,645 shares of the firm's stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $56.11, for a total value of $1,158,390.95. Following the completion of the transaction, the director owned 31,622 shares of the company's stock,
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has approved the previously announced spin-off of First Tracks Biotherapeutics, Inc. (“First Tracks Bio”). The new company is expected to begin “regular-way” trading on the Nasdaq Stock Market LLC (“Nasdaq”) on April 20, 2026, under the ticker symbol “TRAX.”
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the company may repurchase up to $100,000,000 of the company's outstanding common stock, par value $0.001 per share, and provided a business update.
SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB) today announced that its planned spin-off, First Tracks Biotherapeutics, Inc. (“First Tracks Bio”), and EcoR1 Capital (the “Selling Stockholder”) have entered into a purchase agreement with certain third-party investors for a $145 million private placement, before deducting placement agent fees and other expenses.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ANAB.
U.S. House Trading
No House trades found for ANAB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.